Meta-analysis of the effect of statin use and pancreatic cancer risk

doi:10.5246/jcps.2019.12.081

Abstract

Abstract:

Statin has been proposed to have a capacity to reduce the risk of pancreatic cancer, while the obtained results are notconsistent. To gain a clearer picture of the relationship between statin use and pancreatic cancer, the present meta-analysis took into consideration data from eight cohort studies, ten case-control studies and three RCTs.We searched all relevant studies on the effect of statin use on the risk of pancreatic cancer using PubMed, Embase and the Cochrane library database from inception to July 30, 2018. The following search terms were used: (1) statin (“statins”, “statin”, “3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors”, “atorvastatin”, “cerivastatin”, “fluvastatin”, “lovastatin”, “pravastatin”, “rosuvastatin”, “simvastatin”); (2) pancreatic cancer (“cancer”, “neoplasm”, “malignancy”). We manually examined the references of the relevant articles and reviews to identify additional studies. A total of 21studies, published between 2001 and July 2018 and involving 1 148 680 cases and 2 177 842 controls, fulfilled the selection criteria. The pooled results revealed a significant relationship between statin use andpancreatic cancer risk (OR = 0.84, 95% CI 0.72–0.98, P = 0.000, I²= 84.3%). However, lipophilic statins (OR = 1.07, 95% CI 0.97–1.18,P = 0.651, I²= 0.0%) had no significant effect on the risk of pancreatic cancer. In contrast, short-term statin use (OR = 0.72, 95% CI 0.54–0.96, P = 0.000, I²= 80.1%) and long-term statin use (OR = 0.70, 95% CI 0.54–0.92, P = 0.000, I²= 79.8%)significantly reduced pancreatic cancer risk. Notably, the high heterogeneity among the selected studies was eliminated by excluding the three studies that focused on restricted populations. Statin could significantly reduce the risk of pancreatic cancer.

Key words: Pancreatic cancer, Meta-analysis, Statin, Risk, Outcome

CLC Number:

R969

Supporting:

Yao Song, Xiaofei Zhi, Hongyu Zhao, Xingqin Zhou, Wenjuan Chen, Naofumi Mukaida, Qing Lin, Bin Ji. Meta-analysis of the effect of statin use and pancreatic cancer risk[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(12): 855-867.

References

[1] Paulson, A.S.; Tran Cao, H.S.; Tempero, M.A.; Lowy, A.M. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013, 144, 1316-1326.

[2] Downs, J.R.; Clearfield, M.; Weis, S.; Whitney, E.; Shapiro, D.R.; Beere, P.A.; Langendorfer, A.; Stein, E.A.; Kruyer, W.; Gotto, A.M.Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998, 279, 1615-1622.

[3] Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M. Jr, Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Glynn, R.J.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359, 2195-2207.

[4] He, Y.; Huang, H.R.; Farischon, C.; Li, D.L.; Du, Z.Y.; Zhang, K.; Zheng, X.; Goodin, S. Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncol. Rep. 2017, 37, 953-960.

[5] Li, G.; Zheng, J.H.; Xu, B.; Ling, J.; Qiu, W.; Wang, Y.B. Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer. Biomed. Pharmacother. 2017, 85, 418-424.

[6] Liu, Y.H.; Chen, L.; Gong, Z.C.; Shen, L.F.; Kao, C.; Hock, J.M.; Sun, L.Q.; Li, X. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells. Oncotarget. 2015, 6, 3055-3070.

[7] Yang, S.H.; Lin, H.Y.; Chang, V.H.; Chen, C.C.; Liu, Y.R.; Wang, J.H.; Zhang, K.Q.; Jiang, X.Q.; Yen, Y. Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo. Oncotarget. 2015, 6, 23857-23873.

[8] Chen, M.J.; Tsan, Y.T.; Liou, J.M.; Lee, Y.C.; Wu, M.S.; Chiu, H.M.; Wang, H.P.; Chen, P.C. Statins and the risk of pancreatic cancer in Type 2 diabetic patients: A population-based cohort study. Int. J. Cancer. 2016, 138, 594-603.

[9] Walker, E.J.; Ko, A.H.; Holly, E.A.; Bracci, P.M. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer. 2015, 121, 1287-1294.

[10] Khurana, V.; Sheth, A.; Caldito, G.; Barkin, J.S. Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas. 2007, 34, 260-265.

[11] Archibugi, L.; Piciucchi, M.; Stigliano, S.; Valente, R.; Zerboni, G.; Barucca, V.; Milella, M.; Maisonneuve, P.; Delle Fave, G.; Capurso, G. Exclusive and combined use of statins and aspirin and the risk of pancreatic cancer: a case-control study. Sci. Rep. 2017, 7, 13024.

[12] Hamada, T.; Khalaf, N.; Yuan, C.; Babic, A.; Morales Oyarvide V. Statin use and pancreatic cancer risk in two prospective cohort studies. J. Gastroenterol. 2018, 53, 959-966.

[13] Simon, M.S.; Desai, P.; Wallace, R.; Wu, C.Y.; Howard, B.V.; Martin, L.W.; Schlecht, N.; Liu, S.M.; Jay, A.; LeBlanc, E.S.; Rohan, T.; Manson, J. Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative. Cancer Causes Control. 2016, 27, 415-423.

[14] Marelli, C.; Gunnarsson, C.; Ross, S.; Haas, S.; Stroup, D.F.; Cload, P.; Clopton, P.; DeMaria, A.N. Statins and risk of cancer: a retrospective cohort analysis of 45, 857 matched pairs from an electronic medical records database of 11 million adult Americans. J. Am. Coll. Cardiol. 2011, 58, 530-537.

[15] Jacobs, E.J.; Newton, C.C.; Thun, M.J.; Gapstur, S.M. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011, 71, 1763-1771.

[16] Haukka, J.; Sankila, R.; Klaukka, T.; Lonnqvist, J.; Niskanen, L.; Tanskanen, A.; Wahlbeck, K.; Tiihonen, J. Incidence of cancer and statin usage: record linkage study. Int. J. Cancer. 2010, 126, 279-284.

[17] Friedman, G.D.; Flick, E.D.; Udaltsova, N.; Chan, J.; Quesenberry, C.P. Jr, Habel, L.A. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361, 859 recipients. Pharmacoepidemiol. Drug Saf. 2008, 17, 27-36.

[18] Sato, S.; Ajiki, W.; Kobayashi, T.; Awata, N.; PCS Study Group. Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J. Epidemiol. 2006, 16, 201-206.

[19] Kho, P.F.; Fawcett, J.; Fritschi, L.; Risch, H.; Webb, P.M.; Whiteman, D.C.; Neale, R.E. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case-control study. Cancer Causes Control. 2016, 27, 1457-1464.

[20] Carey, F.J.; Little, M.W.; Pugh, T.F.; Ndokera, R.; Ing, H.; Clark, A.; Dennison, A.; Metcalfe, M.S.; Robinson, R.J.; Hart, A.R. The differential effects of statins on the risk of developing pancreatic cancer: a case-control study in two centres in the United Kingdom. Dig. Dis. Sci. 2013, 58, 3308-3312.

[21] Chiu, H.F.; Chang, C.C.; Ho, S.C.; Wu, T.N.; Yang, C.Y. Statin use and the risk of pancreatic cancer: a population-based case-control study. Pancreas. 2011, 40, 669-672.

[22] Bradley, M.C.; Hughes, C.M.; Cantwell, M.M.; Murray, L.J. Statins and pancreatic cancer risk: a nested case-control study. Cancer Causes Control. 2010, 21, 2093-2100.

[23] Coogan, P.F.; Rosenberg, L.; Strom, B.L. Statin use and the risk of 10 cancers. Epidemiology. 2007, 18, 213-219.

[24] Kaye, J.A.; Jick, H. Statin use and cancer risk in the General Practice Research Database. Br. J. Cancer. 2004, 90, 635-637.

[25] Graaf, M.R.; Beiderbeck, A.B.; Egberts, A.C.; Richel, D.J.; Guchelaar, H.J. The risk of cancer in users of statins. J. Clin. Oncol. 2004, 22, 2388-2394.

[26] Strandberg, T.E.; Pyörälä, K.; Cook, T.J.; Wilhelmsen, L.; Faergeman, O.; Thorgeirsson, G.; Pedersen, T.R.; Kjekshus, J.; S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004, 364, 771-777.

[27] Serruys, P.W.; de Feyter, P.; Macaya, C.; Kokott, N.; Puel, J.; Vrolix, M.; Branzi, A.; Bertolami, M.C.; Jackson, G.; Strauss, B.; Meier, B.; Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002, 287, 3215-3222.

[28] Clearfield, M.; Downs, J.R.; Weis, S.; Whitney, E.J.; Kruyer, W.; Shapiro, D.R.; Stein, E.A.; Langendorfer, A.; Beere, P.A.; Gotto, A.M. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J. Womens Health Gend. Based Med. 2001, 10, 971-981.

[29] Bonovas, S.; Filioussi, K.; Sitaras, N.M. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am. J. Gastroenterol. 2008, 103, 2646-2651.

[30] Cui, X.B.; Xie, Y.; Chen, M.; Li, J.; Liao, X.M.; Shen, J.; Shi, M.; Li, W.J.; Zheng, H.X.; Jiang, B. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control. 2012, 23, 1099-1111.

[31] Stroup, D.F.; Berlin, J.A.; Morton, S.C.; Olkin, I.; Williamson, G.D.; Rennie, D.; Moher, D.; Becker, B.J.; Sipe, T.A.; Thacker, S.B. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000, 283, 2008-2012.

[32] Wells, G.A; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Appl. Eng. Agric. 2014, 18, 727-734.

[33] Bardou, M.; Barkun, A.; Martel, M. Effect of statin therapy on colorectal cancer. Gut. 2010, 59, 1572-1585.

[34] DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials. 1986, 7, 177-188.

[35] Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21, 1539-1558.

[36] Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315, 629-634.

[37] Corsini, A.; Bellosta, S.; Baetta, R.; Fumagalli, R.; Paoletti, R.; Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 1999, 84, 413-428.

[38] Anothaisintawee, T.; Udomsubpayakul, U.; McEvoy, M.; Lerdsitthichai, P.; Attia, J.; Thakkinstian, A. Effect of lipophilic and hydrophilic statins on breast cancer risk in Thai women: A cross-sectional study. J. Cancer. 2016, 7, 1163-1168.

[39] Desai, C.S.; Martin, S.S.; Blumenthal, R.S. Non-cardiovascular effects associated with statins. BMJ. 2014, 349, g3743.

[40] Huang, W.Y.; Li, C.H.; Lin, C.L.; Liang, J. Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death. Oncotarget. 2016, 7, 42208-42215.

[41] Liu, Q.F.; Li, Y.; Niu, Z.Y.; Zong, Y.; Wang, M.Y.; Yao, L.T.; Lu, Z.H.; Liao, Q.; Zhao, Y.P. Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages. J. Exp. Clin. Cancer Res. 2016, 35, 33.

[42] Schmid, R.M. HMG-CoA reductase inhibitors for the treatment of pancreatic cancer. Gastroenterology. 2002, 122, 565-567.

[43] Dorais, M.T.R.; Rakel, A.; Lelorrier, J.; Panzini, B. Statins, NSAIDS and pancreatic cancer. Pharmacoepidemiol. Drug Saf. 2007, 16, S93-S93.

[44] Pugh, T.F.; Little, M.W.; Carey, F.J.; Robinson, R.J.; Clark, A.; Metcalfe, M.; Ndokera, R.; Ing, H.; Dennison, A.; Hart, A. Aspirin, NSAIDs, calcium-channel blockers and statins in the aetiology of pancreatic cancer: preliminary results from a case-control study in two centres in the UK. Gastroenterology. 2011, 140, S-401.